A long-term study comparing lacidipine and nifedipine SR in hypertensive patients: safety data.

Abstract

The clinical safety of lacidipine, a new dihydropyridine calcium antagonist, has been assessed in a long-term, comparative study in hypertensive patients. Slow-release (SR) nifedipine was used for comparison. The type and incidence of adverse events seen with both drugs are characteristic of the dihydropyridine class of drugs and were mainly due to pharmacologically induced vasodilation, but lacidipine caused a significantly lower incidence of ankle edema than nifedipine SR. There were no unexpected adverse events during the treatment. The addition of atenolol 50 mg once daily did not increase the frequency of adverse events. Therefore, lacidipine can be considered a safe antihypertensive drug, which can be used as a suitable agent for first-line treatment of hypertension.

• Authors: G Leonetti, S Salvi
• Journal: Journal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 23 Suppl 5 Pg. S108-10 ( 1994) ISSN: 0160-2446 [Print] United States
• PMID: 7609496 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Antihypertensive Agents
• Calcium Channel Blockers
• Delayed-Action Preparations
• Dihydropyridines
• lacidipine
• Atenolol
• Nifedipine

Topics

• Adult
• Aged
• Antihypertensive Agents (adverse effects, therapeutic use)
• Atenolol (therapeutic use)
• Blood Pressure (drug effects)
• Calcium Channel Blockers (therapeutic use)
• Delayed-Action Preparations
• Dihydropyridines (adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Heart Rate (drug effects)
• Humans
• Hypertension (drug therapy, physiopathology)
• Male
• Middle Aged
• Nifedipine (administration & dosage, adverse effects, therapeutic use)
• Single-Blind Method